AIDS-Related Lymphomas

  • Amy Chadburn
  • Ethel Cesarman
Part of the Molecular Pathology Library book series (MPLB, volume 4)


Individuals who are immunodeficient, including those who are HIV infected, have an increased risk of developing lymphoproliferative disorders (LPDs). These lesions in the HIV-infected patient population are somewhat heterogeneous, but are more often clearly benign or malignant than the LPD lesions that arise in other immunodeficient states. Like those occurring in the setting of posttransplantation (also see Chap. 28, methotrexate therapy, primary immune disorders and advanced age, the AIDS-related LPDs are often associated with herpesvirus infection, particularly Epstein–Barr virus (EBV; HHV-4) and Kaposi sarcoma herpesvirus (KSHV; HHV-8). Also similar to the other immunodeficiency-related lymphoproliferations, if the HIV positive patient’s immune status can be restored, such as by highly active antiretroviral therapy (HAART), the lesions may regress. However, in many instances, a secondary genetic alteration, not all of which have been characterized, has occurred resulting in transformation to an irreversible neoplastic process.


Hodgkin Lymphoma Burkitt Lymphoma Immunoglobulin Gene Somatic Hypermutations Primary Effusion Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors wish to extend their gratitude to the AIDS Cancer Specimen Resource for the use of their material for photography, to Dr. Susan Mathew for the cytogenetics images and to Dr. Beverly Nelson for critical reading of the manuscript.


  1. 1.
    Nasta SD, Carrum GM, Shahab I, et al. Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma. 2002;43:423–426.PubMedCrossRefGoogle Scholar
  2. 2.
    Sarkodee-Adoo C, Pittarelli L, Jaffe E, et al. Regression and clonally distinct recurrence of human immunodeficiency virus related Burkitt-like lymphoma during antiretroviral therapy. Leuk Lymphoma. 2001;42:1125–1131.PubMedCrossRefGoogle Scholar
  3. 3.
    Girard T, Luquet-Besson I, Baran-Marszak F, et al. HIV+ MALT lymphoma remission induced by highly active antiretroviral therapy alone. Eur J Haematol. 2005;74:70–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood. 1992;80:8–20.PubMedGoogle Scholar
  5. 5.
    Biggar RJ, Rabkin CS. The epidemiology of AIDS – related neoplasms. Hematol Oncol Clin North Am. 1996;10:997–1010.PubMedCrossRefGoogle Scholar
  6. 6.
    Carbone A, Gaidano G. Acquired immunodeficiency syndrome-related cancer. A study model for the mechanisms contributing to the genesis of cancer. Eur J Cancer. 2001;37:1184–1187.PubMedCrossRefGoogle Scholar
  7. 7.
    Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am. 2003;17:785–820.PubMedCrossRefGoogle Scholar
  8. 8.
    Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood. 2003;102:1833–1841.PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen JI, Bollard CM, Khanna R, et al. Current understanding of the role of Epstein–Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma. 2008;49(suppl 1):27–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of CD40 signals by Epstein–Barr virus LMP1 in B lymphocyte responses. Science. 1999;286:300–303.PubMedCrossRefGoogle Scholar
  11. 11.
    Liebowitz D. Epstein–Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998;338:1413–1421.PubMedCrossRefGoogle Scholar
  12. 12.
    Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997;16:6131–6140.PubMedCrossRefGoogle Scholar
  13. 13.
    Kulwichit W, Edwards RH, Davenport EM, et al. Expression of the Epstein–Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA. 1998;95:11963–11968.PubMedCrossRefGoogle Scholar
  14. 14.
    Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985;43:831–840.PubMedCrossRefGoogle Scholar
  15. 15.
    Homig-Holzel C, Hojer C, Rastelli J, et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med. 2008;205:1317–1329.PubMedCrossRefGoogle Scholar
  16. 16.
    Eliopoulos AG, Stack M, Dawson CW, et al. Epstein–Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene. 1997;14:2899–2916.PubMedCrossRefGoogle Scholar
  17. 17.
    Nakagomi H, Dolcetti R, Bejarano MT, et al. The Epstein–Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer. 1994;57:240–244.PubMedCrossRefGoogle Scholar
  18. 18.
    Gloghini A, Gaidano G, Larocca LM, et al. Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein–Barr virus-encoded latent membrane protein 1. Am J Pathol. 2002;161:163–171.PubMedGoogle Scholar
  19. 19.
    Rowe M, Peng-Pilon M, Huen DS, et al. Upregulation of bcl-2 by the Epstein–Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappaB activation and to induction of cell surface markers. J Virol. 1994;68:5602–5612.PubMedGoogle Scholar
  20. 20.
    Takegawa S, Jin Z, Nakayama T, et al. Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein–Barr virus-associated B-cell lymphoproliferative disorder. Cancer Sci. 2008;99:296–302.PubMedCrossRefGoogle Scholar
  21. 21.
    Brinkmann MM, Schulz TF. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. J Gen Virol. 2006;87:1047–1074.PubMedCrossRefGoogle Scholar
  22. 22.
    Middeldorp JM, Pegtel DM. Multiple roles of LMP1 in Epstein–Barr virus induced immune escape. Semin Cancer Biol. 2008;18:388–396.PubMedCrossRefGoogle Scholar
  23. 23.
    Liu MT, Chang YT, Chen SC, et al. Epstein–Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity. Oncogene. 2005;24:2635–2646.PubMedCrossRefGoogle Scholar
  24. 24.
    Li L, Guo L, Tao Y, et al. Latent membrane protein 1 of Epstein–Barr virus regulates p53 phosphorylation through MAP kinases. Cancer Lett. 2007;255:219–231.PubMedCrossRefGoogle Scholar
  25. 25.
    Rahadiani N, Takakuwa T, Tresnasari K, et al. Latent membrane protein-1 of Epstein–Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines. Biochem Biophys Res Commun. 2008;377:579–583.PubMedCrossRefGoogle Scholar
  26. 26.
    Guasparri I, Bubman D, Cesarman E. EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood. 2008;111:3813–3820.PubMedCrossRefGoogle Scholar
  27. 27.
    Mancao C, Hammerschmidt W. Epstein–Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007;110:3715–3721.PubMedCrossRefGoogle Scholar
  28. 28.
    Mancao C, Altmann M, Jungnickel B, et al. Rescue of “crippled” germinal center B cells from apoptosis by Epstein–Barr virus. Blood. 2005;106:4339–4344.PubMedCrossRefGoogle Scholar
  29. 29.
    Johannsen E, Koh E, Mosialos G, et al. Epstein–Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol. 1995;69:253–262.PubMedGoogle Scholar
  30. 30.
    Muromoto R, Ikeda O, Okabe K, et al. Epstein–Barr virus-derived EBNA2 regulates STAT3 activation. Biochem Biophys Res Commun. 2009;378:439–443.PubMedCrossRefGoogle Scholar
  31. 31.
    Pan SH, Tai CC, Lin CS, et al. Epstein–Barr virus nuclear antigen 2 disrupts mitotic checkpoint and causes chromosomal instability. Carcinogenesis. 2009;30:366–375.PubMedCrossRefGoogle Scholar
  32. 32.
    Tobollik S, Meyer L, Buettner M, et al. Epstein–Barr virus nuclear antigen 2 inhibits AID expression during EBV-driven B-cell growth. Blood. 2006;108:3859–3864.PubMedCrossRefGoogle Scholar
  33. 33.
    Noguchi K, Fukazawa H, Murakami Y, et al. Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies. Cancer Sci. 2007;98:1288–1296.PubMedCrossRefGoogle Scholar
  34. 34.
    Moore PS, Chang Y. Antiviral activity of tumor-suppressor pathways: clues from molecular piracy by KSHV. Trends Genet. 1998;14:144–150.PubMedCrossRefGoogle Scholar
  35. 35.
    Jenner RG, Boshoff C. The molecular pathology of Kaposi’s sarcoma-associated herpesvirus. Biochim Biophys Acta. 2002;1602:1–22.PubMedGoogle Scholar
  36. 36.
    Renne R, Barry C, Dittmer D, et al. Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2001;75:458–468.PubMedCrossRefGoogle Scholar
  37. 37.
    Verma SC, Robertson ES. Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus. FEMS Microbiol Lett. 2003;222:155–163.PubMedCrossRefGoogle Scholar
  38. 38.
    Cotter MA 2nd, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi’s sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology. 1999;264:254–264.PubMedCrossRefGoogle Scholar
  39. 39.
    Garber AC, Shu MA, Hu J, et al. DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2001;75:7882–7892.PubMedCrossRefGoogle Scholar
  40. 40.
    Friborg J Jr, Kong W, Hottiger MO, et al. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999;402:889–894.PubMedGoogle Scholar
  41. 41.
    Verma SC, Lan K, Robertson E. Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol. 2007;312:101–136.PubMedCrossRefGoogle Scholar
  42. 42.
    Godden-Kent D, Talbot SJ, Boshoff C, et al. The cyclin encoded by Kaposi’s sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol. 1997;71:4193–4198.PubMedGoogle Scholar
  43. 43.
    Swanton C, Mann DJ, Fleckenstein B, et al. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature. 1997;390:184–187.PubMedCrossRefGoogle Scholar
  44. 44.
    Chang Y, Moore PS, Talbot SJ, et al. Cyclin encoded by KS herpesvirus. Nature. 1996;382:410.PubMedCrossRefGoogle Scholar
  45. 45.
    Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med. 2004;199:993–1003.PubMedCrossRefGoogle Scholar
  46. 46.
    Chaudhary PM, Jasmin A, Eby MT, et al. Modulation of the NF-kappaB pathway by virally encoded death effector domains-containing proteins. Oncogene. 1999;18:5738–5746.PubMedCrossRefGoogle Scholar
  47. 47.
    Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappa B induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 2000;96:2537–2542.PubMedGoogle Scholar
  48. 48.
    Molden J, Chang Y, You Y, et al. A Kaposi’s sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem. 1997;272:19625–19631.PubMedCrossRefGoogle Scholar
  49. 49.
    Asou H, Said JW, Yang R, et al. Mechanisms of growth control of Kaposi’s sarcoma-associated herpes virus-associated primary effusion lymphoma cells. Blood. 1998;91:2475–2481.PubMedGoogle Scholar
  50. 50.
    Gasperini P, Sakakibara S, Tosato G. Contribution of viral and cellular cytokines to Kaposi’s sarcoma-associated herpesvirus pathogenesis. J Leukoc Biol. 2008;84:994–1000.PubMedCrossRefGoogle Scholar
  51. 51.
    Mori Y, Nishimoto N, Ohno M, et al. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. J Med Virol. 2000;61:332–335.PubMedCrossRefGoogle Scholar
  52. 52.
    Rivas C, Thlick AE, Parravicini C, et al. Kaposi’s sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol. 2001;75:429–438.PubMedCrossRefGoogle Scholar
  53. 53.
    Esteban M, Garcia MA, Domingo-Gil E, et al. The latency protein LANA2 from Kaposi’s sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. J Gen Virol. 2003;84:1463–1470.PubMedCrossRefGoogle Scholar
  54. 54.
    Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97:744–751.PubMedCrossRefGoogle Scholar
  55. 55.
    Ballerini P, Gaidano G, Gong JZ, et al. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma. Blood. 1993;81:166–176.PubMedGoogle Scholar
  56. 56.
    Raphael M, Borisch B, Jaffe E. Lymphomas associated with infection by the human immune deficiency virus (HIV). In: Jaffe E, Harris NL, Stein H, et al., eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC); 2001:260–263.Google Scholar
  57. 57.
    Knowles DM, Chadburn A. Lymphadenopathy and the lymphoid neoplasms associated with the acquired immune deficiency syndrome. In: Knowles DM, ed. Neoplastic Hematopathology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:987–1090.Google Scholar
  58. 58.
    Raphael M, Said J, Borisch B, et al. Lymphomas associated with HIV infections. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC); 2008:340–342.Google Scholar
  59. 59.
    Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60:1365–1372.PubMedCrossRefGoogle Scholar
  60. 60.
    Spina M, Berretta M, Tirelli U. Hodgkin’s disease in HIV. Hematol Oncol Clin North Am. 2003;17:843–858.PubMedCrossRefGoogle Scholar
  61. 61.
    Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108:3786–3791.PubMedCrossRefGoogle Scholar
  62. 62.
    Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973–2003. Cancer Causes Control. 2008;19:841–858.PubMedCrossRefGoogle Scholar
  63. 63.
    Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin’s lymphomas. Burkitt’s Lymphoma Study Group. J Clin Oncol. 1998;16:3788–3795.PubMedGoogle Scholar
  64. 64.
    Miralles P, Berenguer J, Ribera JM, et al. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr. 2007;44:167–173.PubMedCrossRefGoogle Scholar
  65. 65.
    Leoncini L, Raphael M, Stein H, et al. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC); 2008:262–264.Google Scholar
  66. 66.
    Carbone A, Gaidano G, Gloghini A, et al. BCL-6 protein expression in AIDS-related non-Hodgkin’s lymphomas: inverse relationship with Epstein–Barr virus-encoded latent membrane protein-1 expression. Am J Pathol. 1997;150:155–165.PubMedGoogle Scholar
  67. 67.
    Raphael MM, Audouin J, Lamine M, et al. Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas. Correlation with histologic features in 36 cases. French Study Group of Pathology for HIV-Associated Tumors. Am J Clin Pathol. 1994;101:773–782.PubMedGoogle Scholar
  68. 68.
    Pelicci PG, Knowles DM 2nd, Arlin ZA, et al. Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med. 1986;164:2049–2060.PubMedCrossRefGoogle Scholar
  69. 69.
    Capello D, Martini M, Gloghini A, et al. Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin’s lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica. 2008;93:1178–1185.PubMedCrossRefGoogle Scholar
  70. 70.
    Neri A, Barriga F, Knowles DM, et al. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci USA. 1988;85:2748–2752.PubMedCrossRefGoogle Scholar
  71. 71.
    Kelly GL, Rickinson AB. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program. 2007;2007:277–284.Google Scholar
  72. 72.
    Magrath I. The pathogenesis of Burkitt’s lymphoma. Adv Cancer Res. 1990;55:133–270.PubMedCrossRefGoogle Scholar
  73. 73.
    Goossens T, Klein U, Kuppers R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci USA. 1998;95:2463–2468.PubMedCrossRefGoogle Scholar
  74. 74.
    Klein U, Tu Y, Stolovitzky GA, et al. Gene expression dynamics during germinal center transit in B cells. Ann N Y Acad Sci. 2003;987:166–172.PubMedCrossRefGoogle Scholar
  75. 75.
    Robbiani DF, Bothmer A, Callen E, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell. 2008;135:1028–1038.PubMedCrossRefGoogle Scholar
  76. 76.
    Schmidt EV. The role of c-myc in cellular growth control. Oncogene. 1999;18:2988–2996.PubMedCrossRefGoogle Scholar
  77. 77.
    Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA. 2000;97:3260–3265.PubMedCrossRefGoogle Scholar
  78. 78.
    Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene. 1999;18:2916–2924.PubMedCrossRefGoogle Scholar
  79. 79.
    Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene. 2004;23:3217–3221.PubMedCrossRefGoogle Scholar
  80. 80.
    Shiramizu B, Magrath I. Localization of breakpoints by polymerase chain reactions in Burkitt’s lymphoma with 8;14 translocations. Blood. 1990;75:1848–1852.PubMedGoogle Scholar
  81. 81.
    Siebert R, Matthiesen P, Harder S, et al. Application of interphase fluorescence in situ Hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood. 1998;91:984–990.PubMedGoogle Scholar
  82. 82.
    Martin A, Flaman JM, Frebourg T, et al. Functional analysis of the p53 protein in AIDS-related non-Hodgkin’s lymphomas and polymorphic lymphoproliferations. Br J Haematol. 1998;101:311–317.PubMedCrossRefGoogle Scholar
  83. 83.
    Carbone A, Gloghini A, Capello D, et al. Genetic pathways and histogenetic models of AIDS-related lymphomas. Eur J Cancer. 2001;37:1270–1275.PubMedCrossRefGoogle Scholar
  84. 84.
    Lindstrom MS, Wiman KG. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol. 2002;12:381–387.PubMedCrossRefGoogle Scholar
  85. 85.
    Frazier MW, He X, Wang J, et al. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol. 1998;18:3735–3743.PubMedGoogle Scholar
  86. 86.
    Cinti C, Leoncini L, Nyongo A, et al. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt’s lymphoma subtypes. Am J Pathol. 2000;156:751–760.PubMedGoogle Scholar
  87. 87.
    Lazzi S, Bellan C, De Falco G, et al. Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin’s lymphomas: implications for disease pathogenesis. Hum Pathol. 2002;33:723–731.PubMedCrossRefGoogle Scholar
  88. 88.
    Bellan C, Lazzi S, De Falco G, et al. Burkitt’s lymphoma: new insights into molecular pathogenesis. J Clin Pathol. 2003;56:188–192.PubMedCrossRefGoogle Scholar
  89. 89.
    Gaidano G, Lo Coco F, Ye BH, et al. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma: association with diffuse large-cell subtype. Blood. 1994;84:397–402.PubMedGoogle Scholar
  90. 90.
    Subar M, Neri A, Inghirami G, et al. Frequent c-myc oncogene activation and infrequent presence of Epstein–Barr virus genome in AIDS-associated lymphoma. Blood. 1988;72:667–671.PubMedGoogle Scholar
  91. 91.
    Gaidano G, Carbone A, Pastore C, et al. Frequent mutation of the 5′ noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas. Blood. 1997;89:3755–3762.PubMedGoogle Scholar
  92. 92.
    Cesarman E, Chadburn A. Lymphoproliferations of immunodeficiency. In: Leonard DGB, ed. Molecular Pathology in Clinical Practice. New York: Springer Science+Business Media, LLC; 2007:373–382.CrossRefGoogle Scholar
  93. 93.
    Seremetis S, Inghirami G, Ferrero D, et al. Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes. Science. 1989;243:660–663.PubMedCrossRefGoogle Scholar
  94. 94.
    Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood. 2005;106:1031–1036.PubMedCrossRefGoogle Scholar
  95. 95.
    Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–2442.PubMedCrossRefGoogle Scholar
  96. 96.
    Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–2430.PubMedCrossRefGoogle Scholar
  97. 97.
    Rosenwald A, Ott G. Burkitt lymphoma versus diffuse large B-cell lymphoma. Ann Oncol. 2008;19(suppl 4):iv67–iv69.PubMedCrossRefGoogle Scholar
  98. 98.
    Raphael M, Gentilhomme O, Tulliez M, et al. Histopathologic features of high-grade non-Hodgkin’s lymphomas in acquired immunodeficiency syndrome. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors. Arch Pathol Lab Med. 1991;115:15–20.PubMedGoogle Scholar
  99. 99.
    Knecht H, Berger C, Rothenberger S, et al. The role of Epstein–Barr virus in neoplastic transformation. Oncology. 2001;60:289–302.PubMedCrossRefGoogle Scholar
  100. 100.
    Kelly GL, Milner AE, Baldwin GS, et al. Three restricted forms of Epstein–Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci USA. 2006;103:14935–14940.PubMedCrossRefGoogle Scholar
  101. 101.
    Nanbo A, Takada K. The role of Epstein–Barr virus-encoded small RNAs (EBERs) in oncogenesis. Rev Med Virol. 2002;12:321–326.PubMedCrossRefGoogle Scholar
  102. 102.
    Komano J, Maruo S, Kurozumi K, et al. Oncogenic role of Epstein–Barr virus-encoded RNAs in Burkitt’s lymphoma cell line Akata. J Virol. 1999;73:9827–9831.PubMedGoogle Scholar
  103. 103.
    Komano J, Sugiura M, Takada K. Epstein–Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt’s lymphoma cell line Akata. J Virol. 1998;72:9150–9156.PubMedGoogle Scholar
  104. 104.
    Knowles DM, Chamulak GA, Subar M, et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981–1986). Ann Intern Med. 1988;108:744–753.PubMedGoogle Scholar
  105. 105.
    Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107:3832–3840.PubMedCrossRefGoogle Scholar
  106. 106.
    Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2001;98:3406–3412.PubMedCrossRefGoogle Scholar
  107. 107.
    Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood. 2000;96:4084–4090.PubMedGoogle Scholar
  108. 108.
    Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:962–972.PubMedCrossRefGoogle Scholar
  109. 109.
    Stoneburner RL, Sato P, Burton A, et al. The global HIV pandemic. Acta Paediatr Suppl. 1994;400:1–4.PubMedCrossRefGoogle Scholar
  110. 110.
    Knowles DM. The pathology and the pathogenesis of non-Hodgkin’s lymphomas associated with HIV infection. In: Magrath I, ed. The Non-Hodgkin’s Lymphomas. London: Arnold; 1997:471–494.Google Scholar
  111. 111.
    Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood. 2005;106:1762–1769.PubMedCrossRefGoogle Scholar
  112. 112.
    Chadburn A, Silver S, Pasqualucci L, et al. Comparison of AIDS-related diffuse large B-cell lymphomas (AR-DLBCLs) and immunocompetent (IC) DLBCLs suggest biologic differences. Mod Pathol. 2009;22(suppl 1):257A.Google Scholar
  113. 113.
    Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.PubMedCrossRefGoogle Scholar
  114. 114.
    Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653–4659.PubMedCrossRefGoogle Scholar
  115. 115.
    Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium Clinical Trials 010 and 034. J Clin Oncol. 2009;27:5039–5048.PubMedCrossRefGoogle Scholar
  116. 116.
    Vilchez RA, Lopez-Terrada D, Middleton JR, et al. Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin’s lymphoma. Virology. 2005;342:38–46.PubMedCrossRefGoogle Scholar
  117. 117.
    Gormley RP, Madan R, Dulau AE, et al. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases. Am J Clin Pathol. 2005;124:790–798.PubMedCrossRefGoogle Scholar
  118. 118.
    Madan R, Gormley R, Dulau A, et al. AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles. Mod Pathol. 2006;19:438–446.PubMedCrossRefGoogle Scholar
  119. 119.
    Delecluse HJ, Hummel M, Marafioti T, et al. Common and HIV-related diffuse large B-cell lymphomas differ in their immunoglobulin gene mutation pattern. J Pathol. 1999;188:133–138.PubMedCrossRefGoogle Scholar
  120. 120.
    Shiramizu B, Herndier B, Meeker T, et al. Molecular and immunophenotypic characterization of AIDS-associated, Epstein–Barr virus-negative, polyclonal lymphoma. J Clin Oncol. 1992;10:383–389.PubMedGoogle Scholar
  121. 121.
    McGrath MS, Shiramizu B, Meeker TC, et al. AIDS-associated polyclonal lymphoma: identification of a new HIV-associated disease process. J Acquir Immune Defic Syndr. 1991;4:408–415.PubMedGoogle Scholar
  122. 122.
    Carbone A, Gaidano G, Gloghini A, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein–Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas. Blood. 1998;91:747–755.PubMedGoogle Scholar
  123. 123.
    Gaidano G, Vivenza D, Forconi F, et al. Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas. Genes Chromosomes Cancer. 2000;27:177–182.PubMedCrossRefGoogle Scholar
  124. 124.
    Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998;92:1011–1019.PubMedGoogle Scholar
  125. 125.
    Camilleri-Broet S, Davi F, Feuillard J, et al. AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors. Hum Pathol. 1997;28:367–374.PubMedCrossRefGoogle Scholar
  126. 126.
    Julien S, Radosavljevic M, Labouret N, et al. AIDS primary central nervous system lymphoma: molecular analysis of the expressed VH genes and possible implications for lymphomagenesis. J Immunol. 1999;162:1551–1558.PubMedGoogle Scholar
  127. 127.
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.PubMedCrossRefGoogle Scholar
  128. 128.
    Patrone L, Henson SE, Teodorovic J, et al. Gene expression patterns in AIDS versus non-AIDS-related diffuse large B-cell lymphoma. Exp Mol Pathol. 2003;74:129–139.PubMedCrossRefGoogle Scholar
  129. 129.
    Teitell M, Damore MA, Sulur GG, et al. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proc Natl Acad Sci USA. 1999;96:9809–9814.PubMedCrossRefGoogle Scholar
  130. 130.
    Hansen PB, Penkowa M, Kirk O, et al. Human immunodeficiency virus-associated malignant lymphoma in eastern Denmark diagnosed from 1990–1996: clinical features, histopathology, and association with Epstein–Barr virus and human herpesvirus-8. Eur J Haematol. 2000;64:368–375.PubMedCrossRefGoogle Scholar
  131. 131.
    Camilleri-Broet S, Davi F, Feuillard J, et al. High expression of latent membrane protein 1 of Epstein–Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas. Blood. 1995;86:432–435.PubMedGoogle Scholar
  132. 132.
    Camilleri-Broet S, Camparo P, Mokhtari K, et al. Overexpression of BCL-2, BCL-X, and BAX in primary central nervous system lymphomas that occur in immunosuppressed patients. Mod Pathol. 2000;13:158–165.PubMedCrossRefGoogle Scholar
  133. 133.
    Knowles DM, Inghirami G, Ubriaco A, et al. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein–Barr virus. Blood. 1989;73:792–799.PubMedGoogle Scholar
  134. 134.
    Walts AE, Shintaku IP, Said JW. Diagnosis of malignant lymphoma in effusions from patients with AIDS by gene rearrangement. Am J Clin Pathol. 1990;94:170–175.PubMedGoogle Scholar
  135. 135.
    Cesarman E, Chang Y, Moore PS, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–1191.PubMedCrossRefGoogle Scholar
  136. 136.
    Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28:1401–1416.PubMedCrossRefGoogle Scholar
  137. 137.
    Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88:645–656.PubMedGoogle Scholar
  138. 138.
    Carbone A, Gloghini A, Vaccher E, et al. Kaposi’s sarcoma-associated herpesvirus/human herpesvirus type 8–positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn. 2005;7:17–27.PubMedGoogle Scholar
  139. 139.
    Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2008;113:1213–1224.PubMedCrossRefGoogle Scholar
  140. 140.
    Yanagisawa Y, Sato Y, Asahi-Ozaki Y, et al. Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma. J Pathol. 2006;209:464–473.PubMedCrossRefGoogle Scholar
  141. 141.
    Ansari MQ, Dawson DB, Nador R, et al. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol. 1996;105:221–229.PubMedGoogle Scholar
  142. 142.
    Engels EA, Pittaluga S, Whitby D, et al. Immunoblastic lymphoma in persons with AIDS-associated Kaposi’s sarcoma: a role for Kaposi’s sarcoma-associated herpesvirus. Mod Pathol. 2003;16:424–429.PubMedCrossRefGoogle Scholar
  143. 143.
    Chadburn A, Hyjek EM, Tam W, et al. Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD). Histopathology. 2008;53:513–524.PubMedCrossRefGoogle Scholar
  144. 144.
    Deloose ST, Smit LA, Pals FT, et al. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia. 2005;19:851–855.PubMedCrossRefGoogle Scholar
  145. 145.
    Coupland SE, Charlotte F, Mansour G, et al. HHV-8–associated T-cell lymphoma in a lymph node with concurrent peritoneal effusion in an HIV-positive man. Am J Surg Pathol. 2005;29:647–652.PubMedCrossRefGoogle Scholar
  146. 146.
    Boulanger E, Hermine O, Fermand JP, et al. Human herpesvirus 8 (HHV-8)-associated peritoneal primary effusion lymphoma (PEL) in two HIV-negative elderly patients. Am J Hematol. 2004;76:88–91.PubMedCrossRefGoogle Scholar
  147. 147.
    Said JW, Shintaku IP, Asou H, et al. Herpesvirus 8 inclusions in primary effusion lymphoma: report of a unique case with T-cell phenotype. Arch Pathol Lab Med. 1999;123:257–260.PubMedGoogle Scholar
  148. 148.
    Beaty MW, Kumar S, Sorbara L, et al. A biophenotypic human herpesvirus 8 – associated primary bowel lymphoma. Am J Surg Pathol. 1999;23:992–994.PubMedCrossRefGoogle Scholar
  149. 149.
    Gaidano G, Gloghini A, Gattei V, et al. Association of Kaposi’s sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood. 1997;90:4894–4900.PubMedGoogle Scholar
  150. 150.
    Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci USA. 1999;96:4546–4551.PubMedCrossRefGoogle Scholar
  151. 151.
    Ballestas ME, Kaye KM. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J Virol. 2001;75:3250–3258.PubMedCrossRefGoogle Scholar
  152. 152.
    Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science. 1999;284:641–644.PubMedCrossRefGoogle Scholar
  153. 153.
    Foussat A, Wijdenes J, Bouchet L, et al. Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8–infected malignant B lymphocytes. Eur Cytokine Netw. 1999;10:501–508.PubMedGoogle Scholar
  154. 154.
    Horenstein MG, Nador RG, Chadburn A, et al. Epstein–Barr virus latent gene expression in primary effusion lymphomas containing Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8. Blood. 1997;90:1186–1191.PubMedGoogle Scholar
  155. 155.
    Szekely L, Kiss C, Mattsson K, et al. Human herpesvirus-8–encoded LNA-1 accumulates in heterochromatin- associated nuclear bodies. J Gen Virol. 1999;80(pt 11):2889–2900.PubMedGoogle Scholar
  156. 156.
    Boulanger E, Agbalika F, Maarek O, et al. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J. 2001;2:172–179.PubMedCrossRefGoogle Scholar
  157. 157.
    Matolcsy A, Nador RG, Cesarman E, et al. Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am J Pathol. 1998;153:1609–1614.PubMedGoogle Scholar
  158. 158.
    Hamoudi R, Diss TC, Oksenhendler E, et al. Distinct cellular origins of primary effusion lymphoma with and without EBV infection. Leuk Res. 2004;28:333–338.PubMedCrossRefGoogle Scholar
  159. 159.
    Fais F, Gaidano G, Capello D, et al. Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. Leukemia. 1999;13:1093–1099.PubMedCrossRefGoogle Scholar
  160. 160.
    Klein U, Gloghini A, Gaidano G, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood. 2003;101:4115–4121.PubMedCrossRefGoogle Scholar
  161. 161.
    Jenner RG, Maillard K, Cattini N, et al. Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci USA. 2003;100:10399–10404.PubMedCrossRefGoogle Scholar
  162. 162.
    Marshall V, Parks T, Bagni R, et al. Conservation of virally encoded microRNAs in Kaposi sarcoma – associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease. J Infect Dis. 2007;195:645–659.PubMedCrossRefGoogle Scholar
  163. 163.
    O’Hara AJ, Vahrson W, Dittmer DP. Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood. 2008;111:2347–2353.PubMedCrossRefGoogle Scholar
  164. 164.
    Gaidano G, Capello D, Cilia AM, et al. Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. Genes Chromosomes Cancer. 1999;24:16–23.PubMedCrossRefGoogle Scholar
  165. 165.
    Fassone L, Bhatia K, Gutierrez M, et al. Molecular profile of Epstein–Barr virus infection in HHV-8–positive primary effusion lymphoma. Leukemia. 2000;14:271–277.PubMedCrossRefGoogle Scholar
  166. 166.
    Raab-Traub N, Flynn K. The structure of the termini of the Epstein–Barr virus as a marker of clonal cellular proliferation. Cell. 1986;47:883–889.PubMedCrossRefGoogle Scholar
  167. 167.
    Boulanger E, Duprez R, Delabesse E, et al. Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells. Int J Cancer. 2005;115:511–518.PubMedCrossRefGoogle Scholar
  168. 168.
    Gaidano G, Capello D, Fassone L, et al. Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. J Clin Virol. 2000;16:215–224.PubMedCrossRefGoogle Scholar
  169. 169.
    Fan W, Bubman D, Chadburn A, et al. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol. 2005;79:1244–1251.PubMedCrossRefGoogle Scholar
  170. 170.
    Rainbow L, Platt GM, Simpson GR, et al. The 222– to 234–kilodalton latent nuclear protein (LNA) of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol. 1997;71:5915–5921.PubMedGoogle Scholar
  171. 171.
    Katano H, Sato Y, Kurata T, et al. Expression and localization of human herpesvirus 8–encoded proteins in primary effusion lymphoma, Kaposi’s sarcoma, and multicentric Castleman’s disease. Virology. 2000;269:335–344.PubMedCrossRefGoogle Scholar
  172. 172.
    Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–1869.PubMedCrossRefGoogle Scholar
  173. 173.
    Said JW, Chien K, Tasaka T, et al. Ultrastructural characterization of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) in Kaposi’s sarcoma lesions: electron microscopy permits distinction from cytomegalovirus (CMV). J Pathol. 1997;182:273–281.PubMedCrossRefGoogle Scholar
  174. 174.
    Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med. 1996;335:233–241.PubMedCrossRefGoogle Scholar
  175. 175.
    Judde JG, Lacoste V, Briere J, et al. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi’s sarcoma and other diseases. J Natl Cancer Inst. 2000;92:729–736.PubMedCrossRefGoogle Scholar
  176. 176.
    Lacoste V, Judde JG, Bestett G, et al. Virological and molecular characterisation of a new B lymphoid cell line, established from an AIDS patient with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV viruses. Leuk Lymphoma. 2000;38:401–409.PubMedGoogle Scholar
  177. 177.
    Mullaney BP, Ng VL, Herndier BG, et al. Comparative genomic analyses of primary effusion lymphoma. Arch Pathol Lab Med. 2000;124:824–826.PubMedGoogle Scholar
  178. 178.
    Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–1280.PubMedGoogle Scholar
  179. 179.
    Gessain A, Sudaka A, Briere J, et al. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman’s disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood. 1996;87:414–416.PubMedGoogle Scholar
  180. 180.
    Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8–positive plasmablastic lymphoma. Blood. 2000;95:1406–1412.PubMedGoogle Scholar
  181. 181.
    Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman’s disease. Am J Pathol. 1997;151:1517–1522.PubMedGoogle Scholar
  182. 182.
    Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol. 2000;156:743–749.PubMedGoogle Scholar
  183. 183.
    Dargent JL, Lespagnard L, Sirtaine N, et al. Plasmablastic microlymphoma occurring in human herpesvirus 8 (HHV-8)-positive multicentric Castleman’s disease and featuring a follicular growth pattern. APMIS. 2007;115:869–874.PubMedCrossRefGoogle Scholar
  184. 184.
    Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99:2331–2336.PubMedCrossRefGoogle Scholar
  185. 185.
    Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97:2130–2136.PubMedCrossRefGoogle Scholar
  186. 186.
    Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83:804–809.PubMedCrossRefGoogle Scholar
  187. 187.
    Dong HY, Scadden DT, de Leval L, et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein–Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol. 2005;29:1633–1641.PubMedCrossRefGoogle Scholar
  188. 188.
    Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413–1420.PubMedGoogle Scholar
  189. 189.
    Carbone A, Gaidano G, Gloghini A, et al. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann Otol Rhinol Laryngol. 1999;108:95–99.PubMedGoogle Scholar
  190. 190.
    Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004;28:736–747.PubMedCrossRefGoogle Scholar
  191. 191.
    Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18:806–815.PubMedCrossRefGoogle Scholar
  192. 192.
    Wang J, Hernandez OJ, Sen F. Plasmablastic lymphoma involving breast: a case diagnosed by fine-needle aspiration and core needle biopsy. Diagn Cytopathol. 2008;36:257–261.PubMedCrossRefGoogle Scholar
  193. 193.
    Gaidano G, Cerri M, Capello D, et al. Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol. 2002;119:622–628.PubMedCrossRefGoogle Scholar
  194. 194.
    Nador RG, Chadburn A, Gundappa G, et al. Human immunodeficiency virus (HIV)-associated polymorphic lymphoproliferative disorders. Am J Surg Pathol. 2003;27:293–302.PubMedCrossRefGoogle Scholar
  195. 195.
    Tao J, Valderrama E. Epstein–Barr virus-associated polymorphic B-cell lymphoproliferative disorders in the lungs of children with AIDS: a report of two cases. Am J Surg Pathol. 1999;23:560–566.PubMedCrossRefGoogle Scholar
  196. 196.
    Kingma DW, Mueller BU, Frekko K, et al. Low-grade monoclonal Epstein–Barr virus-associated lymphoproliferative disorder of the brain presenting as human immunodeficiency virus-associated encephalopathy in a child with acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1999;123:83–87.PubMedGoogle Scholar
  197. 197.
    Delecluse HJ, Kremmer E, Rouault JP, et al. The expression of Epstein–Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol. 1995;146:1113–1120.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Amy Chadburn
    • 1
  • Ethel Cesarman
    • 2
  1. 1.Department of PathologyNorthwestern University – Feinberg School of MedicineChicagoUSA
  2. 2.Department of Pathology and Laboratory MedicineWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations